Form 8-K · Current Report · Filed 2025-11-05
Halozyme Therapeutics Announces Credit Agreement Amendment and Convertible Notes Offering
Halozyme Therapeutics, Inc. has amended its Credit Agreement to extend the maturity date and increase revolving credit commitments to $750 million. The company also announced a proposed offering of $650 million of convertible senior notes due 2031 and $650 million due 2032, subject to market conditions. The net proceeds from the offering will be used for various corporate purposes, including funding capped call transactions and repurchasing existing convertible notes.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-25-000047
- CIK
- 0001159036
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Creation of a Direct Financial Obligation
Other Events
Market reaction
Close before filing
$68.05
Next session
+0.5%
Since filing
+62.0%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.